ATE422049T1 - Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz - Google Patents

Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz

Info

Publication number
ATE422049T1
ATE422049T1 AT01980518T AT01980518T ATE422049T1 AT E422049 T1 ATE422049 T1 AT E422049T1 AT 01980518 T AT01980518 T AT 01980518T AT 01980518 T AT01980518 T AT 01980518T AT E422049 T1 ATE422049 T1 AT E422049T1
Authority
AT
Austria
Prior art keywords
therapy
therapy resistance
determining critical
critical biological
biological values
Prior art date
Application number
AT01980518T
Other languages
English (en)
Inventor
Kurt Hertogs
Brendan Larder
Richard P Harrigan
Original Assignee
Virco Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virco Bvba filed Critical Virco Bvba
Application granted granted Critical
Publication of ATE422049T1 publication Critical patent/ATE422049T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
AT01980518T 2000-10-20 2001-10-22 Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz ATE422049T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24183600P 2000-10-20 2000-10-20

Publications (1)

Publication Number Publication Date
ATE422049T1 true ATE422049T1 (de) 2009-02-15

Family

ID=22912373

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01980518T ATE422049T1 (de) 2000-10-20 2001-10-22 Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz

Country Status (9)

Country Link
US (1) US7292944B2 (de)
EP (1) EP1340075B1 (de)
JP (1) JP4264256B2 (de)
AT (1) ATE422049T1 (de)
AU (2) AU2002212344B2 (de)
CA (1) CA2425772C (de)
DE (1) DE60137580D1 (de)
ES (1) ES2321809T3 (de)
WO (1) WO2002033402A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246859T3 (es) * 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
EP1356082A2 (de) * 2000-10-20 2003-10-29 Virco Bvba Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-reverse-transkriptase
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
WO2004003227A1 (en) * 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
DE60321466D1 (de) * 2002-07-01 2008-07-17 Tibotec Pharm Ltd Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
EP1520247B1 (de) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
US20050214744A1 (en) * 2002-07-01 2005-09-29 Hilde Azjin New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
CA2557790A1 (en) 2004-03-02 2005-09-15 Virco Bvba Estimation of clinical cut-offs
EP2126137B1 (de) 2007-01-23 2017-06-07 Janssen Pharmaceutica NV Verfahren zur erstellung eines arzneimittelplans für hiv-infizierte patienten
US20080228700A1 (en) 2007-03-16 2008-09-18 Expanse Networks, Inc. Attribute Combination Discovery
CA2688278A1 (en) 2007-05-25 2008-12-04 Tibotec Pharmaceuticals New mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance
US9336177B2 (en) * 2007-10-15 2016-05-10 23Andme, Inc. Genome sharing
US8108406B2 (en) 2008-12-30 2012-01-31 Expanse Networks, Inc. Pangenetic web user behavior prediction system
WO2010077336A1 (en) 2008-12-31 2010-07-08 23Andme, Inc. Finding relatives in a database
CN109273023B (zh) * 2018-09-20 2022-05-17 科大讯飞股份有限公司 一种数据评测方法、装置、设备及可读存储介质
KR102261925B1 (ko) * 2018-12-05 2021-06-04 건국대학교 글로컬산학협력단 메타분석 및 생물경로 기반 기계 학습을 이용한 맞춤형 항암제 내성 예측 방법
US11461193B2 (en) * 2020-09-24 2022-10-04 International Business Machines Corporation Data storage volume recovery management

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100495690B1 (ko) * 1996-01-26 2005-11-08 비르코 비브이비에이 인체 hiv 계통의 표현형적 약제 감수성에 기초한 하나 이상의 최적한 hiv 저해제를 선발하는 방법
EP0852626B1 (de) * 1996-01-29 2002-04-03 Virologic, Inc. Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe
US6103462A (en) * 1998-05-29 2000-08-15 Institut Pasteur Rapid single-cycle assay for human immunodeficiency virus type-1 drug resistance
SE516103C2 (sv) 1998-07-08 2001-11-19 Ericsson Telefon Ab L M Förfarande och anordning i ett paketförmedlingsnät
ES2246859T3 (es) * 1999-05-28 2006-03-01 Virco Bvba Nuevos perfiles mutacionales en la transcriptasa inversa del vih-1 correlacionadas con una resistencia fenotipica a farmacos.
US7138231B2 (en) * 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
EP1352356B1 (de) * 2000-06-08 2009-10-14 Virco Bvba Verfahren um die resistenz gegen ein therapeutisches agenz vorherzusagen unter verwendung neuronaler netze
US7324928B2 (en) * 2002-03-06 2008-01-29 Kitchen Scott G Method and system for determining phenotype from genotype

Also Published As

Publication number Publication date
CA2425772C (en) 2012-07-24
WO2002033402A3 (en) 2002-06-13
EP1340075A2 (de) 2003-09-03
CA2425772A1 (en) 2002-04-25
DE60137580D1 (de) 2009-03-19
WO2002033402A2 (en) 2002-04-25
JP4264256B2 (ja) 2009-05-13
EP1340075B1 (de) 2009-01-28
ES2321809T3 (es) 2009-06-12
US7292944B2 (en) 2007-11-06
AU2002212344B2 (en) 2007-05-17
AU1234402A (en) 2002-04-29
JP2004511800A (ja) 2004-04-15
US20040033489A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
ATE422049T1 (de) Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz
DE69840146D1 (de) Fluoreszenzprotein-sensoren zur erkennung von analyten
DE59806176D1 (de) Messeinrichtung zur Ermittlung von physikalischen und/oder chemischen Eigenschaften von Gasen, Flüssigkeiten und/oder Feststoffen
DK1198585T3 (da) Fremgangsmåde til karakterisering af en biologisk tilstand ved anvendelse af kalibrerede genudtrykkelsesprofiler
DK1077634T3 (da) Monitorering af fysiologiske analytter
DE60216735D1 (de) Mikrokavitätsbiosensor, herstellungsverfahren und verwendungen davon
BR0306588A (pt) Biosensor possuindo eletrodo para determinar a taxa de fluxo de um fluido
DE69330067D1 (de) Analytische testvorrichtung einschliesslich negativ- und positivkontrolle
ATE515693T1 (de) Nachweis einer zielsubstanz in einer probe
DK1311707T3 (da) Massespektroskopisk analyse af biopolymerer
EP1478775A4 (de) Schneller und empfindlicher, auf abstand basierender assay zum nachweis und zur quantifizierung von dna-bindenden proteinen
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE418072T1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE226727T1 (de) Leistungssteigerung von bindungsassays mit verwendung mehr als einer markierungsmittel
Pandey et al. A New Analytical Q‐Absorbance Ratio Method Development and Validation for Simultaneous Estimation of Lamivudine and Isoniazid
ATE472732T1 (de) Testen von analyten mittels immunchromatographie mit lateraler migration
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE454418T1 (de) Chemische sensoren, die anilinpolysiloxane als empfindliche substanzen enthalten, und ihre verwendung zum nachweis und zur quantitativen analyse von nitroverbindungen
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
EP1264897A3 (de) Synthetisches Sensorpeptid für Kinase oder Phosphatase Assays
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
ATE248371T1 (de) Allergennachweis
Breuer et al. A biochemical/biophysical assay dyad for HTS-compatible triaging of inhibitors of the HIV-1 Nef/Hck SH3 interaction
ATE434756T1 (de) Hochempfindliches verfahren zur detektion von unterschieden zwischen den physikalisch messbaren eigenschaften einer probe und einer referenz
Stanley AusDiagnostics SARS-CoV-2 kits shown to be more sensitive than reference laboratory test

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1340075

Country of ref document: EP